Details of the Drug

General Information of Drug (ID: DMUOT9V)

Drug Name

Taxol

Synonyms

C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Pancreatic cancer	2C10	Phase 3	[3]
Gastric adenocarcinoma	2B72	Phase 2	[4]
Ovarian cancer	2C73	Phase 2	[4]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 3

Molecular Weight (mw)

853.9

Logarithm of the Partition Coefficient (xlogp)

2.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C47H51NO14
IUPAC Name: [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
Canonical SMILES: CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
InChI: InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
InChIKey: RCINICONZNJXQF-MZXODVADSA-N

Cross-matching ID

PubChem CID: 36314
ChEBI ID: CHEBI:45863
CAS Number: 33069-62-4
DrugBank ID: DB01229
TTD ID: D0C4RB
ACDINA ID: D01313

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Modulator	[1]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Breast cancer

ICD Disease Classification

2C60-2C65

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Apoptosis regulator Bcl-2 (BCL-2)	DTT	BCL2	2.52E-02	0.17	0.72

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Taxol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Taxol caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[5]
Armodafinil	DMGB035	Minor	Increased metabolism of Taxol caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[6]
LEE011	DMMX75K	Moderate	Decreased metabolism of Taxol caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[5]
-----------

Coadministration of a Drug Treating the Disease Different from Taxol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Taxol caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[7]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Taxol due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[8]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Taxol caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[7]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Taxol due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[9]
Bepridil	DM0RKS4	Moderate	Decreased clearance of Taxol due to the transporter inhibition by Bepridil.	Angina pectoris [BA40]	[10]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Taxol caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[5]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Taxol caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[5]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Taxol and Roflumilast.	Asthma [CA23]	[8]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Taxol caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[5]
ABT-492	DMJFD2I	Minor	Decreased absorption of Taxol due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[11]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Taxol caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[5]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Taxol due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[12]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Taxol caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[7]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Taxol caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Taxol caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[5]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Taxol caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[14]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Taxol caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[5]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Taxol caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[7]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Taxol caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[5]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Taxol caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[7]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Taxol caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[7]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Taxol caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[5]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Taxol caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[15]
Simeprevir	DMLUA9D	Moderate	Decreased clearance of Taxol due to the transporter inhibition by Simeprevir.	Hepatitis virus infection [1E50-1E51]	[10]
Telaprevir	DMMRV29	Major	Decreased metabolism of Taxol caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[15]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Taxol and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[16]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Taxol caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Taxol caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[5]
Saquinavir	DMG814N	Major	Decreased metabolism of Taxol caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Taxol caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Taxol caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[5]
Gemfibrozil	DMD8Q3J	Moderate	Decreased metabolism of Taxol caused by Gemfibrozil mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[5]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Taxol and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[18]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Taxol due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[19]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Taxol due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[9]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Taxol caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[20]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Taxol caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[7]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Taxol and Denosumab.	Low bone mass disorder [FB83]	[21]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Taxol caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[5]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Taxol caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[7]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Taxol caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[5]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Taxol caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[7]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Taxol due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[22]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Taxol caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[5]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Taxol caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[5]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Taxol caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[7]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Taxol caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[7]
Danazol	DML8KTN	Moderate	Decreased metabolism of Taxol caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[5]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Taxol due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[23]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Taxol caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[5]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Taxol and Tecfidera.	Multiple sclerosis [8A40]	[24]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Taxol and Siponimod.	Multiple sclerosis [8A40]	[9]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Taxol and Fingolimod.	Multiple sclerosis [8A40]	[25]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Taxol and Ocrelizumab.	Multiple sclerosis [8A40]	[26]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Taxol and Ozanimod.	Multiple sclerosis [8A40]	[8]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Taxol caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[5]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Taxol caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[27]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Taxol caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[28]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Taxol and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[29]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Taxol due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[30]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Taxol caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[5]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Taxol caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[5]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Taxol caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[31]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Taxol caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[32]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Taxol caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[5]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Taxol caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[5]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Taxol caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[7]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Taxol and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[33]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Taxol and Canakinumab.	Rheumatoid arthritis [FA20]	[34]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Taxol and Rilonacept.	Rheumatoid arthritis [FA20]	[34]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Taxol and Golimumab.	Rheumatoid arthritis [FA20]	[35]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Taxol caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[7]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Taxol when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[36]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Taxol caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[5]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Taxol caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[8]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Taxol caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[37]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Taxol caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[7]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Taxol and Valganciclovir.	Virus infection [1A24-1D9Z]	[9]
-----------


⏷ Show the Full List of 78 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Ethanol	E00023	702	Antimicrobial preservative; Penetration agent; Solvent
Polyoxyl 35 castor oil	E00660	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Paclitaxel 6mg/ml injectable	6mg/ml	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
6	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
7	Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
8	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9	Cerner Multum, Inc. "Australian Product Information.".
10	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
11	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
12	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
13	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
14	Cerner Multum, Inc. "Canadian Product Information.".
15	Bundow D, Aboulafia DM "Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma." Am J Clin Oncol 27 (2004): 81-4. [PMID: 14758138]
16	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
17	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
18	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
19	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
20	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
21	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
22	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
23	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
24	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
25	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
26	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
27	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
28	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
29	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
30	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
31	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
32	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
33	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
34	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
35	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
36	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
37	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.